epocrates

AAN 2024: Pregnancy outcomes of maternal exposure to ocrelizumab

April 17, 2024

In this analysis, investigators found that in utero exposure to ocrelizumab did not increase the risk of adverse pregnancy or infant outcomes compared with previous reports and an epidemiological background of both the multiple sclerosis (MS) and general population. This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS to date.

• 3,253 cumulative MS pregnancies from the Roche safety database were analyzed. A total of 2,446 were reported prospectively, 800 retrospectively, seven unspecified.
• Of the 2,446 prospective pregnancies, 855 (35.0%) had in utero exposure, 575 (23.5%) had no in utero exposure, and 1,016 (41.5%) had unknown exposure.
• Of 855 prospective pregnancies exposed in utero, 512 had known outcomes, including the following: 431 (84.2%) live births; 4 (0.8%) ectopic pregnancies; 38 (7.4%) elective terminations; 38 (7.4%) spontaneous abortions; and 1 (0.2%) stillbirth.

Source:

Bove, R., et al. Pregnancy and infant outcomes in females receiving ocrelizumab for the treatment of multiple sclerosis: analysis of over 3,000 pregnancies to date. Presented at: 2024 American Academy of Neurology Annual Meeting; April 13-18; Denver, CO. https://index.mirasmart.com/AAN2024/PDFfiles/AAN2024-005126.html